
FSSAI Bans Ashwagandha Leaves: Focus on Root-Only Safety
FSSAI Restricts Ashwagandha Use to Roots and Extracts Only
The Food Safety and Standards Authority of India (FSSAI) recently updated the Ashwagandha regulatory guidelines for food products. This new advisory clarifies which parts of the Withania somnifera plant are safe for human consumption in supplements and nutraceuticals. Specifically, the regulator now permits only the roots and their extracts in health supplements. This decision aims to standardize safety across the growing nutraceutical market in India.
Safety Concerns and Ashwagandha Regulatory Guidelines
As per the 2016 Regulations, Schedule IV identifies specific plant parts allowed in food products. Currently, FSSAI allows only Ashwagandha roots due to their well-documented safety profile. However, many manufacturers previously utilized leaves in their formulations. Notably, studies suggest that leaves contain high levels of reactive withanolides like Withaferin-A. This compound may pose safety risks, including potential liver toxicity and gastrointestinal distress. Consequently, the Ministry of Ayush and FSSAI now prohibit leaf extracts in any form to protect public health.
Compliance and Enforcement for Food Business Operators
Food Business Operators (FBOs) must ensure strict adherence to these provisions immediately. Any deviation from these standards will lead to penalties under the Food Safety and Standards Act, 2006. Furthermore, authorities have requested state-level commissioners to maintain strict vigilance. Therefore, licensing officers will monitor product labels to ensure transparency regarding the plant parts used. Additionally, manufacturers must reformulate any products currently containing prohibited leaf material. This alignment between regulators ensures a safer environment for traditional medicine and wellness products.
Frequently Asked Questions
Q1: Which specific parts of the Ashwagandha plant does FSSAI permit in food?
Under the current regulations, FSSAI only permits the use of Ashwagandha roots and their extracts in food products.
Q2: Why did FSSAI ban the use of Ashwagandha leaves?
Authorities banned the leaves because they contain high levels of specific compounds like Withaferin-A, which might cause liver toxicity or neurotoxic effects.
Q3: Does this regulation apply to Ayurvedic drugs as well?
Yes, the Ministry of Ayush has issued similar directives to drug manufacturers to use only roots and avoid leaves in their products.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
- FSSAI issues advisory on Ashwagandha use in food products; permits only rootsand extract - ETHealthworld
- Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016.
- Ministry of Ayush Advisory on the usage of Withania somnifera (Ashwagandha) leaves.

More from MedShots Daily

FSSAI restricts Ashwagandha use in food products to roots and extracts, banning leaves due to safety risks. Manufacturers must comply with the 2016 Regulati...
3 weeks back

A large-scale study reveals that incident arrhythmias during pregnancy are linked to a fourfold increase in heart failure and myocardial infarction risk....
Today

Nurses are essential to healthcare. Learn about the global nurse shortage and their expanding roles in patient safety, digital health, and specialized care....
Today

Explore the shift to zero-fluoroscopy EP procedures, highlighting tools like ICE and 3D mapping that ensure safety without compromising efficacy....
Today

A multicenter study introduces a multimodal AI model integrating MRI and pathology data to accurately predict recurrence in soft tissue sarcoma patients....
Today

A 10-year longitudinal study reveals that long-term glycemic exposure and variability significantly impact cognitive function and impairment risk in older a...
Today